Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.
3d render of immune system T cells attacking cancer cells
April 19, 2021 | Originally published by U.S. Food and Drug Administration (FDA) on April 16, 2021
Focus Areas
Want to find out more about this topic?
Request a FREE Technical Inquiry!